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ABSTRACT
Introduction: The purpose of this study was to
determine the safety, tolerability and
effectiveness of daily administration of an
orally administered pantothenic acid-based
dietary supplement in men and women with
facial acne lesions.
Methods: A randomized, double-blind,
placebo-controlled study of adults previously
diagnosed with mild to moderate acne vulgaris
was performed. Subjects were randomized to
the study agent, a pantothenic acid-based
dietary supplement, or a placebo for 12 weeks
(endpoint). The primary outcome of the study
was the difference in total lesion count between
the study agent group versus the placebo group
from baseline to endpoint. Secondary
measurements included differences in mean
non-inflammatory and inflammatory lesions,
Investigators Global Assessment and
Dermatology Life Quality Index (DLQI) scores
between the two groups. Investigator
assessment of overall improvement and skin
photographs were also taken. Safety and
tolerability endpoints were the assessment of
adverse events and measurement of serum
complete blood count and hepatic function.
Results: Forty-eight subjects were enrolled and
41 were evaluable. There was a significant mean
reduction in total lesion count in the
pantothenic acid group versus placebo at week
12 (P = 0.0197). Mean reduction in
inflammatory lesions was also significantly
reduced and DLQI scores were significantly
lower at week 12 in the pantothenic acid
group versus placebo. The study agent was safe
and well tolerated.
Conclusions: The results from this study
indicate that the administration of a
pantothenic acid-based dietary supplement in
healthy adults with facial acne lesions is safe,
well tolerated and reduced total facial lesion
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count versus placebo after 12 weeks of
administration. Secondary analysis shows that
the study agent significantly reduced area-specific
and inflammatoryblemishes. Further randomized,
placebo-controlled trials are warranted.
Keywords: Acne; Clinical study; Dermatology;
Dietary supplement; Facial lesions; Natural
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INTRODUCTION
Acne is a common disease of the hair follicles in
the skin associated with an oil gland. Facial
lesions due to acne can affect up to 95% of
people during their lifetime and frequently
starts in teens, but often persists or begins
during adulthood [1]. Lesions include non-
inflammatory and inflammatory types. There
are many common treatments for acne lesions
including drugs, over the counter products and
procedures such as laser therapy [2–4]. There
has also been an increasing interest in the use of
natural products for skin health such as vitamin
C, other antioxidants, botanicals and omega-3
fatty acids [5, 6]. One agent that has shown
promise in reducing facial acne lesions is
pantothenic acid (vitamin B5). Pantothenic
acid is a water-soluble member of the
B-vitamin family that is converted into 4’-
phosphopantetheine, which is then converted
to co-enzyme A (CoA) via adenosine
triphosphate [7, 8]. Pantothenic acid regulates
epidermal barrier function and keratinocytes
differentiation via CoA metabolism. Skin
softening ability of pantothenic acid-based
topical products have also been demonstrated
in a recent clinical trial [9–11]. A recent
feasibility study has also shown that daily oral
supplementation of a nutritional agent
containing pantothenic acid for 8 weeks was
feasible and safe. Secondary endpoints of that
study demonstrated that there was a reduction
in total facial acne lesions over the 8-week study
period [12]. Therefore, the purpose of this study
was to further test the pantothenic acid-based
supplement in a randomized, double-blind,
placebo-controlled clinical study to assess the
effectiveness of the study agent in reducing




Fifty-one adult subjects (average age) with C50
non-inflammatory and up to 50 inflammatory
lesions were recruited at 2 dermatology sites.
The main exclusion criteria included pregnancy
and lactation, known allergy or hypersensitivity
to any of the constituents in the study agent
and current use of any prescription treatment
(oral or topical) for acne (washout allowed). Past
use of any procedures including laser therapy,
microdermabrasion and other procedures was
prohibited if the study participant had received
it within the past three months.
Compliance with Ethics
All procedures followed were in accordance
with the ethical standards of the Quorum
Institutional Review Board, Seattle, WA-
Accredited by the Accreditation of Human
Research Protection Programs and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Written informed consent was
obtained from all patients for being included in
the study.
Study Design
The study was performed between August 2012
and November 2013. Once informed consent
94 Dermatol Ther (Heidelb) (2014) 4:93–101
was given, consecutive human subjects with
facial lesions as demonstrated by total lesion
count were assessed and randomized 1:1 to
either the study agent, a pantothenic acid-based
dietary supplement herein referred to as study
agent (PantothenTM, Avilan Marketing LLC,
New York, USA) or an asthetically matched
placebo tablet. The study agent was verified by
the manufacturer to contain the correct dosage
of ingredients as listed (certificate of analysis
not shown). The ingredients in the placebo
table were considered inert and the placebo
tablet did not contain any active ingredients
(certificate of analysis for the placebo tablet not
shown). The dosage of the study agent or the
placebo administered was two tablets taken
orally, twice a day with food for 12 weeks.
Each four-tablet dose of the study agent
contained 2.2 g of pantothenic acid. The
primary outcome of the study was the
reduction in total facial lesions at the study
endpoint (week 12) in the study agent group
versus the placebo group. Secondary outcomes
were changes in non-inflammatory lesions at
specific facial areas, change in inflammatory
lesions (total and specific facial areas), change
in the Investigators Global Assessment (IGA)
and change in scores on the Dermatology Life
Quality Index (DLQI) from baseline to week 12
between the two groups. The DLQI is a general
questionnaire that evaluates quality of life
(QOL) in dermatology patients and consists of
ten questions about symptoms, feelings, daily
activities, type of clothing, social or physical
activities, exercise, job or education,
interpersonal relationships, marriage
relationships, and relationship to dermatologic
symptoms. Higher scores indicate a poorer QOL
[13]. Finally, we assessed investigator overall
improvement as deemed by the study doctor
using a 5-point scale: 2 = marked improvement,
1 = slight improvement, 0 = unchanged,
-1 = worsening, -2 = marked worsening at
the study endpoint (week 12).
Statistics
The study sample size had 80% power to detect
a significant difference in total lesions from
baseline to week 12 of the study between the
two groups and significance was set at 0.05. The
IGA and Investigator Overall Improvement
(IOI) evaluations were performed on a 5-point
scale and transformed to numerical values (0–5)
and the mean, standard deviation and
percentages were calculated. Differences in
DQLI scores were analyzed from baseline to
week 12 using a t test. A last observation carried
forward method was prospectively defined and
used for missing data if the subjects had data at
least for the first two visits. The tolerability and
safety outcome was the incidence of adverse
effects, complication/illness and/or serious
medical events due to the study agent as
measured by the National Cancer Institute’s
(NCI) Common Criteria for Adverse Event
Reporting Version 3.0 [14] and by analysis of
serum complete blood count and hepatic
function from baseline to week 12 (EsoterixTM,
LabCorp, Cranford, NJ, USA). Descriptive
analyses were performed for demographics
utilizing characteristic measures such as mean,
standard deviation, and range.
RESULTS
Subjects
Fifty-one subjects were screened, forty-eight
were randomized and forty-one subjects were
evaluable. Of those, five subjects were lost to
follow-up, one withdrew consent and one was
dropped for non-compliance. None of the
subjects were terminated due to an adverse
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event (AE) (see Fig. 1 for study flow).
Demographics and baseline characteristics are
listed in Table 1.
Efficacy Analysis
Primary Endpoint
There was a statistically significant decrease in
the number of total facial lesions over the study
period in the subjects taking the study agent
versus placebo (P = 0.0197) (Fig. 2). Lesion
count in the study agent versus placebo group
was reduced by 68.21%.
Secondary Endpoints
Analysis of the number of non-inflammatory
blemishes demonstrated a significant mean
reduction in lesion count from baseline to
week 12 in the study agent versus the placebo
group (P = 0.0162) (Fig. 3). Breakdown of
changes in lesion count per facial area also
demonstrated significance in numerous
categories in the study agent versus placebo
group (Fig. 3). Overall efficacy, as measured by
the IGA, was significantly improved for the
study agent group versus placebo at week 12
(P = 0.045) as 42.85% versus 14.28% were
downgraded to grade 1 (almost clear skin, few
non-inflammatory lesions and no more than 1
inflammatory lesion). Figure 4a, b demonstrates
examples of clearer skin in both inflammatory
and non-inflammatory blemishes from baseline
versus week 12 in subjects in the study agent
group.
Fig. 1 Consort diagram representing subject ﬂow
throughout the study






N 20 21 –
Mean age, years
(SD)
29.7 (7.5) 27.1 (3.8) –
Sex
Male 3 2 –
Female 17 19 –
BMI (SD)
All 26.2 (5.7) 26.1 (6.7) –
Race (no. [%])
White 10 [52.6] 10 [47.6] –
Black 6 [31.6] 4 [19.05] –
Asian 2 [10.5] 4 [19.05] –
Other 1 [5.3 3 [14.3] –
Ethnicity
Latino 3 [15.8] 3 [14.3] –
Non-Latino 16 [84.2] 18 [85.7] –
Baseline blemish count [mean (SD)]
Total mean (SD) 51.3 (22.4) 71.8 (42.8) 0.071
Non-
inﬂammatory
41.2 (16.7) 48.9 (33.7) 0.374
Inﬂammatory 15.3 (8.9) 17.3 (14.3) 0.603
BMI body mass index, SD standard deviation
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Dermatology Life Quality Index (DLQI)
and Overall Investigator Assessment
of Improvement
The mean ± standard deviation (SD) DLQI score
was lower at week 12 from baseline between the
study agent and placebo group (baseline scores,
7.6 ± 5.3 versus 9.53 ± 7.69, P = 0.44 study
agent versus placebo, versus week 12 scores,
1.93 ± 1.90 and 5.3 ± 4.8 study agent versus
placebo, respectively, P = 0.022). The overall
investigator assessment of improvement at
week 12 as measured by a 5-point scale
demonstrated that 85.7% of subjects had C1
rank improvement in the study agent versus the
placebo group (35.7%).
Primary Safety and Tolerability Endpoints
The study agent was well tolerated. One subject
withdrew consent due to complaint that the
tablet size was too large. There were no
differences in complete blood count or hepatic
function as measured at week 12 from baseline
in any subjects in either the study agent or
placebo groups (data not shown). There were
two AEs reported, one of fatigue (placebo group)
and one of shingles (study agent group) that
were deemed unrelated to the study agent by
the study principal investigator. No serious AEs
were reported during the study.
DISCUSSION
Pantothenic acid (vitamin B5) is a water-soluble
B-complex vitamin. In this study, volunteers
Fig. 2 Difference in total lesion count between study
agent and placebo at week 12. *P = 0.0197 study agent
versus placebo
Fig. 3 Lesion count by facial area at week 12. *P = 0.0162, **P = 0.018, ^P = 0.0024, ?P=0.0192
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with facial lesions who took a daily oral dose of
a pantothenic acid-based dietary supplement
demonstrated improved skin health versus
those who took a placebo tablet. The results of
this study further confirmed that it was safe and
tolerable for healthy human volunteers to take a
nutritional supplement containing pantothenic
acid for 12 weeks. The results of this study
showed that there was a greater than 67%
reduction in the number of total facial lesions
after 12 weeks of supplementation. Results also
demonstrated that there was a significant
reduction in the number of total and specific
facial areas in non-inflammatory lesions after
12 weeks in the pantothenic acid group,
improved scores on the IGA and improved
overall investigators assessment at study
endpoint. In addition, subjects in the study
agent group demonstrated better quality of life
as measured by the DLQI [13]; a well-validated
quantitative questionnaire that measures the
bother of unclear skin on patients’ QOL with
regard to social, behavioral and mood
indicators. Most importantly, the study agent
Fig. 4 a Representative photograph of forehead non-
inﬂammatory lesion at baseline versus week 12 in a single
subject in the study agent group. b Representative
photograph of a subject with mixed lesions (chin and
cheek, inﬂammatory and non-inﬂammatory) at baseline
versus week 12, single subject in the study agent group
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was well tolerated and safe as demonstrated by
minimal adverse events and no changes in
serum blood chemistries.
The mechanism by which this occurs may be
due to antibacterial and skin softening activity
of pantothenic acid. Pantothenic acid is
converted into 40-phosphopantetheine that is
then converted to CoA via adenosine
triphosphate (ATP) [7]. CoA is a critical agent
important in lipid metabolism and other
cellular processes and it has been shown that
pantothenic acid may regulate epidermal
barrier function through proliferation and
differentiation of keratinocytes via CoA
metabolism [7, 15]. It is possible that the
reduction in the amount of global skin lesions
in volunteers following oral administration of
the pantothenic acid-based study agent may
function through these mechanisms. However,
the exact mechanism of this effect is not
understood. More recently the association
between CoA metabolism and inflammation has
also been suggested as it has been shown that the
pantetheinase enzyme that recycles pantothenic
acid and pantetheinase gene (vanin-1) knockout
mice has been shown to be involved in the
progression of inflammatory reactions [16]. The
bioavailability of pantothenic acid has been
reported in the range of 40–63% and amounts
found in 24-h urine samples have been shown to
correlate with this intake [17]. For example,
avocados contain a wide variety of essential
nutrients including pantothenic acid and
essential fatty acids and studies have
demonstrated that these correlate with improved
health in persons who consume them [18].
In addition to physiologic mechanisms of
action, this study also demonstrated that
volunteers in the study agent group who
demonstrated clear skin had improved quality
of life as measured by a well-validated,
quantitative questionnaire. It has been clearly
shown that acne patients with poor facial skin
have reduced quality of life with regard to
dissatisfaction about appearance, social bother
and even co-morbid depression. It has also been
stressed that assessment of quality of life in
studies testing any type of agent for facial acne
lesions is important and strongly correlates with
treatment success [19, 20].
Limitations of this study are its short duration
intervention and that the study was powered to
detect a difference in total lesions. If we aimed to
look at the effects of the study agent in
inflammatory lesions, a longer intervention
period may be needed. Moreover, we are unable to
measure long-term useanddurability. Finally, there
is always a possibility that milder, non-
inflammatory lesions may resolve on their own by
chance. Given that administration of study agent
was safe, tolerable and demonstrated improvement
in human facial lesions, further randomized,
placebo-controlled studies are warranted.
CONCLUSIONS
The results from this study indicate that the
administration of a pantothenic-based dietary
supplement in healthy human adults with facial
lesions is safe, well tolerated and reduces total
facial lesion count versus placebo after 12 weeks of
administration. Secondary analysis shows that
administration of the study agent significantly
reduced area-specific and inflammatory lesions.
Further randomized, placebo-controlled trials are
warranted.
ACKNOWLEDGMENTS
Sponsorship for this study was provided by Avilan
Marketing LLC (Brooklyn, NY, USA). Article
processing charge was provided by Nutraceutical
Medical Research (New York, NY, USA).
Dermatol Ther (Heidelb) (2014) 4:93–101 99
Staff at Manhattan Medical Research (New
York, USA) and Union Square Laser Dermatology
(New York, USA) helped to provide care for study
participants.
All named authors meet the ICMJE criteria
for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval for the
version to be published.
Conflict of interest. MYang, B Moclair, V
Hatcher, J Kaminetsky, M Mekas, A Chapas and
J Capodice declare no conflict of interest.
Compliance with ethics. All procedures
followed were in accordance with the ethical
standards of the Quorum Institutional Review
Board, Seattle, WA-Accredited by the
Accreditation of Human Research Protection
Programs and with the Helsinki Declaration of
1975, as revised in 2000 and 2008. Written
informed consent was obtained from all
patients for being included in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Goulden V, Stables GI, Cunliffe WJ. Prevalence of
facial acne in adults. J Am Acad Dermatol.
1999;41(4):577–80.
2. Ingram JR, Grindlay DJ, Williams HC. Management
of acne vulgaris: an evidence-based update. Clin
Exp Dermatol. 2010;35(4):351–4.
3. Knutsen-Larson S, Dawson AL, Dunnick CA,
Dellavalle RP. Acne vulgaris: pathogenesis,
treatment, and needs assessment. Dermatol Clin.
2012;30(1):99–106.
4. Williams HC, Dellavalle RP, Garner S. Acne
vulgaris. Lancet. 2012;379(9813):361–72.
5. Magin PJ, Adams J, Heading GS, Pond DC, Smith W.
Complementary and alternative medicine therapies
in acne, psoriasis, and atopic eczema: results of a
qualitative study of patients’ experiences and
perceptions. J Altern Complement Med.
2006;12(5):451–7.
6. El-Akawi Z, Abdel-Latif N, Abdul-Razzak K. Does the
plasma level of vitamins A and E affect acne
condition? Clin Exp Dermatol. 2006;31(3):430.
7. Kelly GS. Pantothenic acid. Monograph. Altern Med
Rev. 2011;16(3):263–74.
8. Leung LH. Pantothenic acid deficiency as the
pathogenesis of acne vulgaris. Med Hypotheses.
1995;44(6):490–2.
9. Kobayashi D, Kusama M, Onda M, Nakahata N. The
effect of pantothenic acid deficiency on
keratinocyte proliferation and the synthesis of
keratinocyte growth factor and collagen in
fibroblasts. J Pharmacol Sci. 2011;115(2):230–4.
10. Jerajani HR, Mizoguchi H, Li J, Whittenbarger DJ,
Marmor MJ. The effects of a daily facial lotion
containing vitamins B3 and E and provitamin B5
on the facial skin of Indian women: a randomized,
double-blind trial. Indian J Dermatol Venereol
Leprol. 2010;76(1):20–6.
11. Camargo FB Jr, Gaspar LR, Maia Campos PM. Skin
moisturizing effects of panthenol-based
formulations. J Cosmet Sci. 2011;62(4):361–70.
12. Capodice JL. Feasibility, tolerability, safety and
efficacy of a pantothenic acid based dietary
supplement in subjects with mild to moderate
facial acne blemishes. J Cosmet Dermatol Sci
Appl. 2012;2:132–5.
13. Finlay AY, Khan GK. Dermatology Life Quality Index
(DLQI)—a simple practical measure for routine
clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
14. Cancer Therapy Evaluation Program, Common
Terminology Criteria for Adverse Events, Version
3.0, DCTD, NCI, NIH, DHHS; 2003. http://ctep.
cancer.gov. Last accessed April 17, 2014.
15. Gaisa NT, Ko¨ster J, Reinartz A, Ertmer K, Ehling J,
Raupach K, Perez-Bouza A, Knu¨chel R, Gassler N.
Expression of acyl-CoA synthetase 5 in human
epidermis. Histol Histopathol. 2008;23(4):451–8.
16. Nitto T, Onodera K. The linkage between coenzyme
a metabolism and inflammation: roles of
pantetheinase. J Pharmacol Sci. 2013;123(1):1–8
Epub 2013 Aug 24.
100 Dermatol Ther (Heidelb) (2014) 4:93–101
17. Eissenstat BR, Wyse BW, Hansen RG. Pantothenic
acid status of adolescents. Am J Clin Nutr.
1986;44(6):931–7.
18. Dreher ML, Davenport AJ. Hass avocado
composition and potential health effects. Crit Rev
Food Sci Nutr. 2013;53(7):738–50.
19. Barnes LE, Levender MM, Fleischer AB Jr, Feldman
SR. Quality of life measures for acne patients.
Dermatol Clin. 2012;30(2):293–300.
20. Gollnick HP, Finlay AY, Shear N. Global Alliance to
Improve Outcomes in Acne. Can we define acne as
a chronic disease? If so, how and when? Am J Clin
Dermatol. 2008;9(5):279–84.
Dermatol Ther (Heidelb) (2014) 4:93–101 101
